Mangoceuticals (MGRX) Stock Overview
Engages in the development, marketing, and sale of various men’s wellness products and services through a telemedicine platform in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
MGRX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Mangoceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.39 |
| 52 Week High | US$2.75 |
| 52 Week Low | US$0.16 |
| Beta | 2.05 |
| 1 Month Change | -29.49% |
| 3 Month Change | 7.93% |
| 1 Year Change | -81.92% |
| 3 Year Change | -97.58% |
| 5 Year Change | n/a |
| Change since IPO | -99.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| MGRX | US Consumer Retailing | US Market | |
|---|---|---|---|
| 7D | -1.4% | -3.1% | -2.2% |
| 1Y | -81.9% | 2.0% | 13.1% |
Return vs Industry: MGRX underperformed the US Consumer Retailing industry which returned 3.7% over the past year.
Return vs Market: MGRX underperformed the US Market which returned 14.8% over the past year.
Price Volatility
| MGRX volatility | |
|---|---|
| MGRX Average Weekly Movement | 33.5% |
| Consumer Retailing Industry Average Movement | 5.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.4% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: MGRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MGRX's weekly volatility (33%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 3 | Jacob Cohen | www.mangoceuticals.com |
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men’s wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also provides oral testosterone undecanoate to treat low testosterone in men and as a form of testosterone replacement therapy under the Prime brand; and access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations.
Mangoceuticals, Inc. Fundamentals Summary
| MGRX fundamental statistics | |
|---|---|
| Market cap | US$7.14m |
| Earnings (TTM) | -US$16.57m |
| Revenue (TTM) | US$315.23k |
Is MGRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MGRX income statement (TTM) | |
|---|---|
| Revenue | US$315.23k |
| Cost of Revenue | US$143.64k |
| Gross Profit | US$171.59k |
| Other Expenses | US$16.75m |
| Earnings | -US$16.57m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.97 |
| Gross Margin | 54.43% |
| Net Profit Margin | -5,257.67% |
| Debt/Equity Ratio | 0% |
How did MGRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/10 00:22 |
| End of Day Share Price | 2026/09/10 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mangoceuticals, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.